In addition, Ginsenoside Rd displayed the therapeutic function to EAE specifically by modulating inflammation and autoimmunity, via the downregulation of related proinflammatory cytokines IL-6 and IL-17, upregulation of inhibitory cytokines TGF-β and IL-10, and regulation of Treg/Th17 imbalance. The gene discussed is IL17A; the disease is Autoimmunity.